Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 1921 to 1935 of 7682 results

  1. Bentracimab for reversing the antiplatelet activity of ticagrelor TS ID 10550

    Awaiting development [GID-TA11354] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Pariglasgene brecaparvovec for treating glycogen storage disease type 1a in people 8 years and over TS ID 11865

    Awaiting development [GID-TA11358] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Beremagene geperpavec for treating skin wounds associated with dystrophic epidermolysis bullosa [ID3959]

    Awaiting development [GID-TA10868] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Renal cell carcinoma Pathways Pilot [ID6186]

    In development [GID-TA11186] Expected publication date: TBC

    Technology appraisal guidance
    In development

  5. Deucravacitinib for treating active psoriatic arthritis TS ID 11981

    Awaiting development [GID-TA11510] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Lurbinectedin with atezolizumab for maintenance treatment of extensive-stage small-cell lung cancer TS ID 11970

    Awaiting development [GID-TA11502] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Subcutaneous efgartigmod with recombinant human hyaluronidase PH20 for treating primary immune thrombocytopenia TS ID 11977

    Awaiting development [GID-TA11507] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. MIM8 for preventing bleeding episodes in haemophilia A in people 1 year and over ID6400

    Awaiting development [GID-TA11509] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Virtual Wards for Heart Failure

    Awaiting development [GID-MT609] Expected publication date: TBC

    Medical technologies guidance
    Awaiting development

  10. Digital platforms to support cardiac rehabilitation

    Awaiting development [GID-MT607] Expected publication date: TBC

    Medical technologies guidance
    Awaiting development

  11. Virtual Wards for COPD exacerbations

    Awaiting development [GID-MT608] Expected publication date: TBC

    Medical technologies guidance
    Awaiting development

  12. Daratumumab in combination for untreated multiple myeloma when high-dose chemotherapy and autologous stem cell transplant are suitable ID6249

    Awaiting development [GID-TA11254] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. Sabatolimab with azacitidine for untreated high-risk myelodysplastic syndromes [ID3996]

    Awaiting development [GID-TA10897] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Venetoclax with azacitidine for untreated high-risk myelodysplastic syndromes [ID6314]

    In development [GID-TA11368] Expected publication date: TBC

    Technology appraisal guidance
    In development

  15. Treatments for non-small-cell lung cancer [ID6234]

    In development [GID-TA11289] Expected publication date: TBC

    Technology appraisal guidance
    In development